A Trial Evaluating Maintenance Therapy With Lamivudine (Epivir®) and Dolutegravir (Tivicay®) in Human Immunodeficiency Virus 1 (HIV-1) Infected Patients Virologically Suppressed With Triple Highly Active Antiretroviral Therapy (HAART) (ANRS 167 Lamidol)

Condition: HIV-1 InfectionInterventions: Drug: dolutegravir (Tivicay®) - Phase 1; Drug: lamivudine (Epivir®) - Phase 2; Drug: dolutegravir (Tivicay®) - Phase 2Sponsors: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS); ViiV HealthcareNot yet recruiting - verified August 2015

http://clinicaltrials.gov/ct2/show/NCT02527096?lup_s=08%2F01%2F2015&lup_d=30

Source: ClinicalTrials.gov - August 6, 2015 Category: Research Source Type: clinical trials